BTIG has given Tiziana Life Sciences a Buy rating with a $7 price target, highlighting its nasal spray drug foralumab as a promising treatment for neurodegenerative diseases like multiple sclerosis, multiple system atrophy, and Alzheimer's. The drug stimulates regulatory T-cells to reduce inflammation in the central nervous system, a key factor in these diseases. Upcoming clinical trial results, especially from the INFORM-MS trial in October, could validate the drug's effectiveness and reduce investment risk. The approach is notable for its ease of delivery and safety profile compared to other immune therapies.
Lululemon Athletica's shares dropped sharply by 19.22% to $98.37, reaching their lowest level since 2018 after the company reported disappointing earnings and revenue guidance. The firm missed revenue estimates and forecasted lower sales for Q3 and t...
Lemonade launched a new insurance product in Missouri offering Tesla drivers a 50% discount on miles driven using Tesla's Full Self-Driving (FSD) technology. This discount is based on Lemonade's analysis of crash data showing FSD reduces accident ris...
The tokenized asset market grew nearly 50% in 2026, reaching $37 billion, but only 12% of these assets are fully integrated into decentralized finance (DeFi) ecosystems, according to Centrifuge's Tokenization Snapshot 2026. Most tokenized assets act ...
Campbell's announced a 36% cut to its quarterly dividend, the first since 2001, to strengthen its balance sheet amid significant losses in its snack segment. While its Meals & Beverages division showed growth, the snack business saw a 12% revenue dec...
UBS has reaffirmed its 'buy' rating on Tesco with a 12-month price target of 545p, implying a 16.45% potential return. The broker highlights Tesco's rapid completion of 73% of its £750 million annual share buyback in the first half, the fastest pace ...
